Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OSTX Stock Forecast 2025-2026
$1.64
Current Price
$35.96M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to OSTX Price Targets
+1,119.5%
To High Target of $20.00
+753.7%
To Median Target of $14.00
+265.9%
To Low Target of $6.00
OSTX Price Momentum
-15.9%
1 Week Change
+7.2%
1 Month Change
0.0%
1 Year Change
-61.7%
Year-to-Date Change
-76.6%
From 52W High of $7.00
+46.4%
From 52W Low of $1.12
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching OS Therapies (OSTX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on OSTX and similar high-potential opportunities.
Latest OSTX Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, OSTX has a bullish consensus with a median price target of $14.00 (ranging from $6.00 to $20.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $1.64, the median forecast implies a 753.7% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 1,119.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OSTX Analyst Ratings
4
Buy
0
Hold
0
Sell
OSTX Price Target Range
Low
$6.00
Average
$14.00
High
$20.00
Current: $1.64
Latest OSTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OSTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Apr 22, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Apr 7, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Apr 2, 2025 | Lake Street | Chad Messer | Buy | Initiates | $19.00 |
| Mar 31, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Feb 24, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Feb 20, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Feb 4, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Jan 30, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Jan 16, 2025 | Maxim Group | Jason McCarthy | Buy | Maintains | $15.00 |
| Jan 15, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $20.00 |
| Nov 26, 2024 | Maxim Group | Jason McCarthy | Buy | Initiates | $8.00 |
| Oct 3, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $21.00 |
| Sep 16, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $21.00 |
| Sep 3, 2024 | EF Hutton | Jason Kolbert | Buy | Initiates | $21.00 |
Os Therapies Inc. (OSTX) Competitors
The following stocks are similar to OS Therapies based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Os Therapies Inc. (OSTX) Financial Data
Os Therapies Inc. has a market capitalization of $35.96M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -1,341.5%.
Valuation Metrics
Market Cap
$35.96M
Enterprise Value
$36.48M
P/E Ratio
0.0x
PEG Ratio
1.1x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+15.5%
Current Ratio
1.2x
Debt/Equity
0.0x
ROE
-1,341.5%
ROA
-134.4%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Os Therapies Inc. (OSTX) Business Model
About Os Therapies Inc.
What They Do
Develops innovative cancer treatments through biotechnology.
Business Model
Os Therapies Inc. generates revenue by researching and commercializing immunotherapy products aimed at improving cancer treatment. The company engages in clinical trials to validate the efficacy of its therapies, which can then be marketed to healthcare providers and patients.
Additional Information
The company is positioned within the biotechnology and pharmaceutical industries, contributing to advancements in personalized medicine. Its focus on harnessing the immune system for cancer treatment aligns with current trends in oncology, making it a potentially impactful player in addressing significant healthcare challenges.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
4
CEO
Mr. Paul A. Romness M.P.H.
Country
United States
IPO Year
2024
Website
ostherapies.comOs Therapies Inc. (OSTX) Latest News & Analysis
Latest News
Quick Summary
OS Therapies Inc. (NYSE-A: OSTX) reported positive data from its OST-HER2 Phase 2b trial for preventing lung metastasis in its Q1 2025 financial results, indicating significant progress for the company.
Why It Matters
Positive trial results can enhance OS Therapies' market position and attract investor interest, potentially driving stock price appreciation and future funding opportunities.
Source: Business Wire
Market Sentiment:
Neutral
OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma
3 days ago
Quick Summary
OS Therapies (NYSE-A: OSTX) launched OS Animal Health, a subsidiary aimed at commercializing OST-HER2 for canine osteosarcoma, targeting a market opportunity exceeding $150 million.
Why It Matters
OS Therapies' launch of OS Animal Health and its focus on a market exceeding $150 million signals potential revenue growth and diversification, enhancing investor interest and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
OS Therapies (NYSE-A: OSTX) secured a US patent for manufacturing methods related to its listeria monocytogenes cancer immunotherapy, valid until 2040, and is pursuing FDA approval for OST-HER2.
Why It Matters
The patent protection until 2040 enhances OS Therapies' competitive advantage and potential revenue from its cancer immunotherapy platform, increasing investor confidence in future growth.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The trailer for the documentary "Shelter Me: The Cancer Pioneers" has been released. It will stream on PBS app and PBS.org starting May 15, showcasing dogs aiding in cancer treatment advancements.
Why It Matters
The release of "Shelter Me: The Cancer Pioneers" could boost PBS viewership and streaming subscriptions, potentially enhancing funding and support for future content and partnerships.
Source: Business Wire
Market Sentiment:
Neutral
OS Therapies FDA Meeting Request Granted
26 days ago
Quick Summary
OS Therapies (NYSE-A: OSTX) announced that the FDA has approved its meeting request to discuss surrogate endpoints for Breakthrough Therapy Designation and Accelerated Approval of OST-HER2 for lung metastatic osteosarcoma.
Why It Matters
The FDA's meeting approval for OS Therapies indicates potential for expedited drug approval, which could enhance the company's market position and attract investment interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
OS Therapies (NYSE-A: OSTX) has acquired listeria-based cancer immunotherapy assets from Advaxis Immunotherapies, positioning itself as a leader in this emerging category.
Why It Matters
OS Therapies' acquisition enhances its market position in cancer immunotherapy, potentially driving future revenue growth and innovation, which could attract investor interest and increase stock value.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About OSTX Stock
What is Os Therapies Inc.'s (OSTX) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Os Therapies Inc. (OSTX) has a median price target of $14.00. The highest price target is $20.00 and the lowest is $6.00.
Is OSTX stock a good investment in 2025?
According to current analyst ratings, OSTX has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.64. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OSTX stock?
Wall Street analysts predict OSTX stock could reach $14.00 in the next 12 months. This represents a 753.7% increase from the current price of $1.64. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Os Therapies Inc.'s business model?
Os Therapies Inc. generates revenue by researching and commercializing immunotherapy products aimed at improving cancer treatment. The company engages in clinical trials to validate the efficacy of its therapies, which can then be marketed to healthcare providers and patients.
What is the highest forecasted price for OSTX Os Therapies Inc.?
The highest price target for OSTX is $20.00 from Jason Kolbert at D. Boral Capital, which represents a 1,119.5% increase from the current price of $1.64.
What is the lowest forecasted price for OSTX Os Therapies Inc.?
The lowest price target for OSTX is $6.00 from at , which represents a 265.9% increase from the current price of $1.64.
What is the overall OSTX consensus from analysts for Os Therapies Inc.?
The overall analyst consensus for OSTX is bullish. Out of 3 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $14.00.
How accurate are OSTX stock price projections?
Stock price projections, including those for Os Therapies Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 18, 2025 9:21 AM UTC